03 Mar
Congress’ Remedy for Post-marketing
When the Food and Drug Administration (FDA) approved Merck’s quadrivalent human papillomavirus vaccine (Gardasil) on June 8, 2006, the agency extracted some post-approval commitments from the company, as it frequently does when it “green-lights” an important new drug around which questions still revolve. Those commitments involved additional testing of Gardasil after it went on the [...]